Can Obama Help Vete...
Health Care: Drugs
Affymax Inc. (AFFY: NASDAQ)
$13.35 -0.79 | -5.59%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.29 | 0.58 | 0.98 |
| Price to Sales (TTM) | 5.11 | 4.62 | 1.42 |
| Price to Book (MRQ) | 4.29 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 4.29 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -26.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -6.70 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 278.90 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -57.60 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 20.38 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -18.31 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 6.90 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 7.10 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.08 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.09 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | -19.00 | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -94.27 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -21.60 | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -68.90 | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.22 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -70.00 | 5.30 | 7.00 |
| Return on Assets (TTM) | -12.00 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -32.90 | 2.20 | 2.50 |
| Return on Investment (TTM) | -16.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -91.20 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 724,969.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -156,331.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 3.20 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.60 | 0.40 | 0.40 |
Portfolios with AFFY
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserBurrdee
- ContributorStocks At New 52-Week Highs...
- Usersimulator
- Contributor10 Biotech Stocks on Clinic...
- UserPART 5 JPMorgan 28th Annual...
Latest AFFY Headlines from TheStreet
- 8 Stocks Rising on Monster Volume 04.02.12 | 01:04 pm
- Biotech Stock Mailbag: MAP Pharma, Affymax 03.30.12 | 05:03 am
- 8 Stocks Rising on Huge Volume 03.23.12 | 02:03 pm
- Biotech Stock Mailbag: Xoma's Big Backers, FDA Approvals Contest 03.23.12 | 05:03 am
- The Next Big Thing in Biotech: FDA Decisions
03.23.12 | 05:03 am - Biotech Stock Chat: Recap 03.15.12 | 11:03 am
- 5 Stocks Ready to Soar on Bullish Earnings 03.13.12 | 06:03 am
- More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More 02.29.12 | 07:02 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- 6 Stocks at New 52-Week Highs 02.14.12 | 02:02 pm
Press Releases for AFFY
- Affymax To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 06.01.12 | 08:06 am
- Affymax Reports First Quarter 2012 Financial Results - Business Wire 05.07.12 | 04:05 pm
- Affymax And Takeda Announce Centers For Medicare And Medicaid Services Has Assigned A Q-Code For OMONTYS® (Peginesatide) Injection - Business Wire 04.13.12 | 08:04 am
- Affymax Receives A $50 Million Milestone Payment For U.S. Approval Of OMONTYS® (peginesatide) Injection - Business Wire 04.09.12 | 04:04 pm
- Affymax And Takeda Announce FDA Approval Of OMONTYS® (Peginesatide) Injection For The Treatment Of Anemia Due To Chronic Kidney Disease (CKD) In Adult Patients On Dialysis - Business Wire 03.27.12 | 02:03 pm
- Affymax® Reports Year End 2011 Financial Results - Business Wire 03.14.12 | 04:03 pm
- Affymax Announces Yearend 2011 Financial Results Teleconference And Webcast - Business Wire 03.07.12 | 04:03 pm
- Affymax To Receive $5 Million Milestone Payment For Acceptance Of European Marketing Authorization Application For Peginesatide - Business Wire 02.27.12 | 08:02 am
- Affymax Announces Upcoming Webcasts And Conference Participation - Business Wire 02.21.12 | 04:02 pm
- Affymax To Present At 14th Annual BIO CEO & Investor Conference - Business Wire 02.08.12 | 04:02 pm
Partner Headlines for AFFY
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 05.23.12 | 09:05 am
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Cramer's Lightning Round - Danaher Has Good Blood Lines (2/10/12) - Seeking Alpha 02.12.12 | 07:02 am
- Affymax Spiking Higher on Heavy Volume - Benzinga 12.27.11 | 01:12 pm
- 7 Stocks With Unusual Options Activity - Seeking Alpha 12.09.11 | 09:12 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Company News for December 6, 2011 - Corporate Summary - Zacks 12.06.11 | 10:12 am
